Project Summary

Rael D. Strous, M.D. (Young Investigator 2003) of Sackler School of Medicine, will study the management of negative symptoms of schizophrenia (i.e. social withdrawal and apathy) and neurocognitive dysfunction, as previous research has been insufficient and incomplete.  Dehydropiandrosterone (DHEA) is a neurosteroid which has demonstrated effectiveness in the enhancement of mood, improvement of aggression and cognitive function in animal and human populations, as well as controlling weight gain and management of glucose dysregulation.  Dr. Strous will investigate the efficacy of DHEA in the management of neurocognitive dysfunction, aggressive behavior and the control of olanzapine-induced weight gain and glucose metabolism in subjects with schizophrenia.  This research may reveal the potential role of DHEA in the management and relief of negative symptoms and cognitive impairment in schizophrenia.

Program Area: SCHIZOPHRENIA/PSYCHOTIC DISORDERS\Schizophrenia\Pharmacology

Search Again